Skip to main content

Find Clinical Trials

Home
Conditions
Hemoglobinuria, Paroxysmal

Clinical trial condition

Hemoglobinuria, Paroxysmal

Explore clinical trials studying Hemoglobinuria, Paroxysmal. Study availability and eligibility vary by location and protocol.

159 public trials 28 recruiting studies

Refine in advanced search Browse all conditions

Hemoglobinuria, Paroxysmal trial results

Recruiting

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

NCT06412497

Conditions: Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Acquired amegakaryocytic thrombocytopenia, +11 more
Locations: University of Minnesota Masonic Cancer Center Minneapolis, Minnesota, United States

View Trial Details

Recruiting

A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China

NCT06931691

Conditions: Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations: Novartis Investigative Site Hefei, Anhui, China

Novartis Investigative Site Guangzhou, Guangdong, China

Novartis Investigative Site Guangzhou, Guangdong, China

Novartis Investigative Site Shijiazhuang, Hebei, China

View all 14 locations

View Trial Details

Recruiting

A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT07256301

Conditions: Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations: The Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences) Tianjin, Tianjin Municipality, China

The First Affiliated Hospital, Zhejiang University School of Medicine, Chengzhan Campus Hangzhou, Zhejiang, China

View Trial Details

Recruiting

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

NCT06934967

Conditions: Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations: Cancer Institute of New Jersey New Brunswick, New Jersey, United States

Childrens Hospital of Philadelphia Philadelphia, Pennsylvania, United States

St Jude Childrens Research Hospital Memphis, Tennessee, United States

Novartis Investigative Site Brasília, Federal District, Brazil

View all 13 locations

View Trial Details

Recruiting

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

NCT06312644

Conditions: Anemia, Anemia, Hemolytic, Atypical Hemolytic Uremic Syndrome, +44 more
Locations: Research Site Boston, Massachusetts, United States

Research Site Melbourne, Victoria, Australia

Research Site Paris, France

Research Site Essen, Norte-Westfalia, Germany

View Trial Details

Recruiting

Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT07470762

Conditions: Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations: The First Affiliated Hospital，Zhejiang University School of Medicine Hangzhou, Zhejiang, China

View Trial Details

Recruiting

A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants

NCT07462780

Conditions: Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +6 more
Locations: Peking University Third Hospital Beijing, China

View Trial Details

Recruiting

National Longitudinal Cohort of Hematological Diseases

NCT04645199

Conditions: Acute Myeloid Leukemia, Anemia, Anemia, Aplastic, +53 more
Locations: Institute of Hematology & Blood Diseases Hospital Tianjin, Tianjin Municipality, China

View Trial Details

Recruiting

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

NCT06449001

Conditions: Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +10 more
Locations: Research Site Saskatoon, Saskatchewan, Canada

Research Site Paris, France

Research Site Leeds, United Kingdom

Research Site London, United Kingdom

View Trial Details

Recruiting

Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment

NCT07152288

Conditions: Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations: Peking University First Hospital Beijing, China

View Trial Details